Center for Scientific Review; Notice of Closed Meetings, 22552-22553 [2017-09780]
Download as PDF
<![CDATA[
22552
Federal Register / Vol. 82, No. 93 / Tuesday, May 16, 2017 / Notices
pain, chronic pain and chronic pain
management, and disparities in pain
and pain care will provide a framework
for development of the strategy upon
which important cross-cutting elements
will be addressed.
Meeting Location: William H. Natcher
Conference Center, Auditorium,
National Institutes of Health, Bethesda,
MD 20892.
Webcast Live: https://
videocast.nih.gov/.
Contact Person: Linda L. Porter,
Ph.D., Director, Office of Pain Policy,
Officer of the Director, National Institute
of Neurological Disorders and Stroke,
NIH, 31 Center Drive, Room 8A31,
Bethesda, MD 20892, Phone: (301) 451–
4460, Email: Linda.Porter@nih.gov.
The meeting is open to the public and
is free. More information can be found
at https://iprcc.nih.gov/.
Individuals who participate in person
or by videocast and who need special
assistance, such as captioning of the call
or other reasonable accommodations,
should submit a request to the Contact
Person listed on this notice at least
seven days prior to the meeting.
Information about the IPRCC and the
Federal Pain Research Strategy is
available on the Web site at https://
iprcc.nih.gov/.
Dated: May 3, 2017.
Walter J. Koroshetz,
Director, National Institute of Neurological
Disorders and Stroke, National Institutes of
Health.
[FR Doc. 2017–09860 Filed 5–15–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
sradovich on DSK3GMQ082PROD with NOTICES
National Cancer Institute; Notice of
Charter Renewal
In accordance with Title 41 of the
U.S. Code of Federal Regulations,
Section 102–3.65(a), notice is hereby
given that the Charter for the Frederick
National Laboratory Advisory
Committee to the National Cancer
Institute (FNLAC) was renewed for an
additional two-year period on March 30,
2017.
It is determined that the FNLAC is in
the public interest in connection with
the performance of duties imposed on
the Department of Health and Human
Services by law, and that these duties
can best be performed through the
advice and counsel of this group.
Inquiries may be directed to Jennifer
Spaeth, Director, Office of Federal
Advisory Committee Policy, Office of
VerDate Sep<11>2014
16:42 May 15, 2017
Jkt 241001
the Director, National Institutes of
Health, 6701 Democracy Boulevard,
Suite 1000, Bethesda, Maryland 20892
(Mail code 4875), Telephone (301) 496–
2123, or spaethj@od.nih.gov.
Dated: May 10, 2017.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–09794 Filed 5–15–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Clinical Oncology Study Section.
Date: June 12, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton La Jolla Hotel, 3299
Holiday Court, La Jolla, CA 92037.
Contact Person: Malaya Chatterjee, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6192,
MSC 7804, Bethesda, MD 20892, 301–806–
2515, chatterm@csr.nih.gov.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Language and Communication Study
Section.
Date: June 12–13, 2017.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The William F. Bolger Center, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: Wind Cowles, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3172,
Bethesda, MD 20892, 301–437–7872,
cowleshw@csr.nih.gov.
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
Group; Aging Systems and Geriatrics Study
Section.
Date: June 12–13, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Inese Z. Beitins, M.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6152,
MSC 7892, Bethesda, MD 20892, 301–435–
1034, beitinsi@csr.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Community-Level Health Promotion Study
Section.
Date: June 12–13, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Wardman Park Washington
DC Hotel, 2660 Woodley Road NW.,
Washington, DC 20008.
Contact Person: Ping Wu, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 3166, Bethesda, MD 20892, 301–
451–8428, wup4@csr.nih.gov.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Basic Mechanisms of Cancer
Therapeutics Study Section.
Date: June 12–13, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz-Carlton Hotel, 1700 Tysons
Boulevard, McLean, VA 22102.
Contact Person: Lambratu Rahman Sesay,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
MSC 7804, Bethesda, MD 20892, 301–451–
3493, rahman-sesayl@csr.nih.gov.
Name of Committee: Oncology 1—Basic
Translational Integrated Review Group;
Cancer Genetics Study Section.
Date: June 12–13, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Juraj Bies, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4158, MSC 7806, Bethesda, MD
20892, 301–435–1256, biesj@mail.nih.gov.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Drug Discovery and Molecular
Pharmacology Study Section.
Date: June 12–13, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Dupont Circle Hotel, 1500 New
Hampshire Avenue NW., Washington, DC
20036.
Contact Person: Jeffrey Smiley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
E:\FR\FM\16MYN1.SGM
16MYN1
Federal Register / Vol. 82, No. 93 / Tuesday, May 16, 2017 / Notices
Health, 6701 Rockledge Drive, Room 6194,
MSC 7804, Bethesda, MD 20892, 301–594–
7945, smileyja@csr.nih.gov.
Name of Committee: Musculoskeletal, Oral
and Skin Sciences Integrated Review Group;
Arthritis, Connective Tissue and Skin Study
Section.
Date: June 12–13, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Long Beach and Executive
Center, 701 West Ocean Boulevard, Long
Beach, CA 90831.
Contact Person: Alexey Belkin, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4102,
Bethesda, MD 20817, 301–435–1786,
alexey.belkin@nih.gov.
Name of Committee: Infectious Diseases
and Microbiology Integrated Review Group;
Clinical Research and Field Studies of
Infectious Diseases Study Section.
Date: June 12–13, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Cambria Hotel and Suites, 1 Helen
Heneghan Way, Rockville, MD 20850.
Contact Person: Soheyla Saadi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3211,
MSC 7808, Bethesda, MD 20892, 301–435–
0903, saadisoh@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 10, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–09780 Filed 5–15–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Invention;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government.
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive Room 4A29,
VerDate Sep<11>2014
16:42 May 15, 2017
Jkt 241001
MSC 2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION: The
following inventions are available for
licensing in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Technology description
follows.
Efficient mRNA-Based Genetic
Engineering of Human NK Cells With
High-Affinity CD16 and CCR7
Description of Technology: A highly
efficient method to genetically modify
natural killer (NK) cells to induce
expression of high affinity CD16 (HA–
CD16) through mRNA electroporation,
to potentiate NK cell-mediated
antibody-dependent cellular
cytotoxicity (ADCC). ADCC is mediated
by CD16+ NK cells following adoptive
NK cell transfer, but most humans
express CD16 which has a relatively low
affinity for IgG1 antibodies. However, a
single nucleotide polymorphism (SNP
rs396991) in the CD16 gene, resulting in
an amino acid substitution at position
158 (F158V), is associated with
substantially higher affinity and
superior NK cell-mediated ADCC than
those with the 158F genotype. This HA–
CD16–158V polymorphism has also
been linked to enhanced ADCC capacity
in vivo. The nearly 100% efficiency of
our method resulted in: (a) Sustained
surface expression of transgenes at high
levels for up to 4 days without
compromising NK cell cytotoxicity and
viability; and (b) augmented ADCC
against Daratumumab coated multiple
myeloma cells by ex vivo expanded NK
cells electroporated with mRNA coding
for HA–CD16. This system is GMP
compliant and has been used previously
in FDA approved clinical trials.
Potential Commercial Applications:
Infusion of a large number of highly
cytotoxic autologous ex vivo expanded
NK cells expressing high-affinity CD16
into patients, to induce a more profound
anti-malignancy response to specific
monoclonal antibodies, including:
multiple myeloma (Daratumumab);
lymphoma (Rituximab); breast cancer
(Trastuzumab); and colon cancer
(Cetuximab).
Development Stage: Early-stage; In
vitro data available.
Inventors: Richard W. Childs and
Mattias Carlsten (NHLBI).
Publications:
(1) Carlsten M, Levy E, Karambelkar
A, Li L, Reger R, Berg M, Peshwa MV
and Childs RW (2016) Efficient mRNA-
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
22553
Based Genetic Engineering of Human
NK Cells with High-Affinity CD16 and
CCR7 Augments Rituximab-Induced
ADCC against Lymphoma and Targets
NK Cell Migration toward the Lymph
Node-Associated Chemokine CCL19.
Front. Immunol. 7:105. doi: 10.3389/
fimmu.2016.00105.
(2) Carlsten M and Childs RW (2015)
Genetic manipulation of NK cells for
cancer immunotherapy: techniques and
clinical implications. Front. Immunol.
6:266. doi: 10.3389/fimmu.2015.00266.
Intellectual Property: NIH Reference
No. E–036–2015/0,1—US Application
No. 62/079,975, filed 14 Nov 2014; and
PCT Application No. PCT/US2015/
060646, filed 13 Nov 2015.
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301–435–4507; thalhamc@mail.nih.gov.
Dated: May 4, 2017.
Cristina Thalhammer-Reyero,
Senior Licensing and Patenting Manager,
Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.
[FR Doc. 2017–09791 Filed 5–15–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Minority Health
and Health Disparities; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Minority Health and Health Disparities,
Special Emphasis Panel; NIH Support for
Conferences and Scientific Meeting—DRI
(01).
Date: June 19, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Gateway Plaza, 533J, 7201 Wisconsin
Avenue, Suite 533, Bethesda, MD 20814
(Teleconference).
E:\FR\FM\16MYN1.SGM
16MYN1
]]>Agencies
[Federal Register Volume 82, Number 93 (Tuesday, May 16, 2017)]
[Notices]
[Pages 22552-22553]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-09780]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Oncology 2--Translational Clinical Integrated
Review Group; Clinical Oncology Study Section.
Date: June 12, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Sheraton La Jolla Hotel, 3299 Holiday Court, La Jolla, CA
92037.
Contact Person: Malaya Chatterjee, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6192, MSC 7804, Bethesda, MD
20892, 301-806-2515, chatterm@csr.nih.gov.
Name of Committee: Biobehavioral and Behavioral Processes
Integrated Review Group; Language and Communication Study Section.
Date: June 12-13, 2017.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: The William F. Bolger Center, 9600 Newbridge Drive,
Potomac, MD 20854.
Contact Person: Wind Cowles, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3172, Bethesda, MD 20892, 301-437-7872,
cowleshw@csr.nih.gov.
Name of Committee: Brain Disorders and Clinical Neuroscience
Integrated Review Group; Aging Systems and Geriatrics Study Section.
Date: June 12-13, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road NW., Washington, DC 20015.
Contact Person: Inese Z. Beitins, M.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6152, MSC 7892, Bethesda, MD
20892, 301-435-1034, beitinsi@csr.nih.gov.
Name of Committee: Healthcare Delivery and Methodologies
Integrated Review Group; Community-Level Health Promotion Study
Section.
Date: June 12-13, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Marriott Wardman Park Washington DC Hotel, 2660 Woodley
Road NW., Washington, DC 20008.
Contact Person: Ping Wu, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3166, Bethesda, MD 20892, 301-451-8428,
wup4@csr.nih.gov.
Name of Committee: Oncology 2--Translational Clinical Integrated
Review Group; Basic Mechanisms of Cancer Therapeutics Study Section.
Date: June 12-13, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Ritz-Carlton Hotel, 1700 Tysons Boulevard, McLean, VA
22102.
Contact Person: Lambratu Rahman Sesay, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD
20892, 301-451-3493, rahman-sesayl@csr.nih.gov.
Name of Committee: Oncology 1--Basic Translational Integrated
Review Group; Cancer Genetics Study Section.
Date: June 12-13, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Washington/Rockville, 1750 Rockville Pike,
Rockville, MD 20852.
Contact Person: Juraj Bies, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4158, MSC 7806, Bethesda, MD 20892, 301-435-
1256, biesj@mail.nih.gov.
Name of Committee: Oncology 2--Translational Clinical Integrated
Review Group; Drug Discovery and Molecular Pharmacology Study
Section.
Date: June 12-13, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: The Dupont Circle Hotel, 1500 New Hampshire Avenue NW.,
Washington, DC 20036.
Contact Person: Jeffrey Smiley, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
[[Page 22553]]
Health, 6701 Rockledge Drive, Room 6194, MSC 7804, Bethesda, MD
20892, 301-594-7945, smileyja@csr.nih.gov.
Name of Committee: Musculoskeletal, Oral and Skin Sciences
Integrated Review Group; Arthritis, Connective Tissue and Skin Study
Section.
Date: June 12-13, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Long Beach and Executive Center, 701 West Ocean
Boulevard, Long Beach, CA 90831.
Contact Person: Alexey Belkin, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4102, Bethesda, MD 20817, 301-435-1786,
alexey.belkin@nih.gov.
Name of Committee: Infectious Diseases and Microbiology
Integrated Review Group; Clinical Research and Field Studies of
Infectious Diseases Study Section.
Date: June 12-13, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Cambria Hotel and Suites, 1 Helen Heneghan Way,
Rockville, MD 20850.
Contact Person: Soheyla Saadi, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3211, MSC 7808, Bethesda, MD 20892, 301-435-
0903, saadisoh@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: May 10, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-09780 Filed 5-15-17; 8:45 am]
BILLING CODE 4140-01-P
